9 Participants Needed

Genetically Modified T Cells + Decitabine for Ovarian Cancer

No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

This trial studies a treatment combining enhanced immune cells and a drug to target difficult-to-treat ovarian and related cancers. The approach aims to improve the body's ability to find and destroy cancer cells.

Research Team

Emese Zsiros MD, PhD, FACOG | Roswell ...

Emese Zsiros

Principal Investigator

Roswell Park Cancer Institute

Eligibility Criteria

This trial is for patients with recurrent or refractory ovarian, primary peritoneal, or fallopian tube cancer. Participants must have HLA-A*02;01 positivity, good performance status (ECOG 0-1), life expectancy over 4 months, adequate organ function and blood counts, measurable disease by irRECIST criteria, and be at least 4 weeks out from prior treatments. Women of childbearing potential must agree to use effective contraception.

Inclusion Criteria

I agree to use effective birth control methods during and after the study for several years.
Leukocytes >= 3 x 10^9/L
Patient must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure
See 13 more

Exclusion Criteria

I do not have any ongoing illnesses or social situations that would prevent me from following the study's requirements.
I do not have active hepatitis C or have a recent test showing I'm clear of it.
Lack of availability of a patient for immunological and clinical follow-up assessment
See 13 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Patients receive decitabine IV daily over 1 hour on days -8 to -6, cyclophosphamide IV over 2 hours on days -4 and -3, and genetically engineered NY-ESO-1-specific T lymphocytes IV and IP on day 0, followed by low-dose IL-2 for 2 weeks from Day 1 to Day 14.

3 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

Up to 15 years
Monthly at 3-9 months, every 6 months for 4 years, then annually

Treatment Details

Interventions

  • Decitabine
  • Genetically Engineered NY-ESO-1-specific T Lymphocytes
Trial Overview The trial is testing the safety of genetically modified T cells designed to target NY-ESO-1 protein on tumor cells combined with Decitabine in patients whose cancer has returned or hasn't responded to treatment. Patients' own T cells are collected and engineered before being reintroduced into their body alongside Decitabine to potentially enhance the immune response against cancer.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Treatment (decitabine, genetically modified T cells)Experimental Treatment5 Interventions
COURSE 1: Patients receive decitabine IV daily over 1 hour on days -8 to -6, cyclophosphamide IV over 2 hours on days -4 and -3, and genetically engineered NY-ESO-1-specific T lymphocytes IV and IP on day 0. Patients also receive aldesleukin SC BID on days 1-14..

Decitabine is already approved in European Union, United States, Canada, Japan for the following indications:

πŸ‡ͺπŸ‡Ί
Approved in European Union as Dacogen for:
  • Acute myeloid leukemia
  • Myelodysplastic syndromes
πŸ‡ΊπŸ‡Έ
Approved in United States as Dacogen for:
  • Myelodysplastic syndromes
  • Acute myeloid leukemia
πŸ‡¨πŸ‡¦
Approved in Canada as Dacogen for:
  • Myelodysplastic syndromes
  • Acute myeloid leukemia
πŸ‡―πŸ‡΅
Approved in Japan as Dacogen for:
  • Myelodysplastic syndromes
  • Acute myeloid leukemia

Find a Clinic Near You

Who Is Running the Clinical Trial?

Roswell Park Cancer Institute

Lead Sponsor

Trials
427
Recruited
40,500+

National Cancer Institute (NCI)

Collaborator

Trials
14,080
Recruited
41,180,000+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of ServiceΒ·Privacy PolicyΒ·CookiesΒ·Security